公开(公告)号：US20100056608A1

公开(公告)日：2010-03-04

申请号：US12515344

申请日：2007-11-19

Applicant: Johan Bjorkegren ,  Jesper Tegner

Inventor： Johan Bjorkegren ,  Jesper Tegner

IPC: A61K31/7088 ,  C12Q1/68 ,  C12N5/10 ,  A01K67/00

CPC classification number: G01N33/5023 ,  A61K38/1709 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/323 ,  Y02A50/465

Abstract: The present invention relates to a method for identifying a compound as a candidate drug, comprising the steps a. bringing said compound into contact with a cell expressing the genes CYPC, AGPAT3, AGL, PVRL2, HMGB 3, HSDL2; and b. analyzing if said compound modulates the expression of at least one of said genes. It also relates to a method for identifying a compound as a candidate drug, comprising the steps a. bringing said compound into contact with a cell expressing the gene LDB2; and b. analyzing if said compound modulates the expression of LDB2. The invention further relates to genetically modified cells and animals useful in such methods and to methods for treatment of atherosclerosis, atherosclerosis-related diseases or inflammatory diseases, comprising the use of such identified compounds.

Abstract translation: 本发明涉及鉴定化合物作为候选药物的方法，包括步骤a。 使所述化合物与表达CYPC，AGPAT3，AGL，PVRL2，HMGB3，HSDL2基因的细胞接触; 和b。 分析所述化合物是否调节至少一种所述基因的表达。 它还涉及用于鉴定化合物作为候选药物的方法，包括步骤a。 使所述化合物与表达基因LDB2的细胞接触; 和b。 分析所述化合物是否调节LDB2的表达。 本发明还涉及可用于这些方法的遗传修饰的细胞和动物，以及用于治疗动脉粥样硬化，动脉粥样硬化相关疾病或炎性疾病的方法，其包括使用这种鉴定的化合物。